Mary Eapen, MRCPI, MS, MBBS

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English

Education

MRCPI - Gen Med Royal College of Phy of Ireland
MS -Master of Science
MBBS - Doctor of Medicine

Biography

Dr. Eapen received her MBBS from Ahmadu Bello University, Zaria, Nigeria, in 1987. She completed a pediatric residency in 1997. In 2000, Dr. Eapen completed a fellowship in hematology/oncology/blood and bone marrow transplant and a MS in Clinical Research at the University of Minnesota, Minneapolis, Minnesota.

Research Interests

Mary Eapen, MD, MS, is Professor at the Medical College of Wisconsin and Senior Scientific Director - Research, Center for International Blood and Marrow Transplant Research. Her research focuses on the use of graft sources other than bone marrow for allogeneic hematopoietic cell transplantation for acute leukemia and marrow failure disorders.

Choosing donors in clinical practice.

(Eapen M.) Blood. 2024 Jul 18;144(3):248-249 PMID: 39023876 SCOPUS ID: 2-s2.0-85198150047 07/18/2024
Immunosuppression with post-transplant cyclophosphamide for allogeneic hematopoietic cell transplantation.

(Eapen M.) Haematologica. 2024 Jul 01;109(7):2024-2025 PMID: 38946648 PMCID: PMC11215355 SCOPUS ID: 2-s2.0-85197633211 07/01/2024
Navigating Treatment Options and Communication in Relapsed Pediatric AML.

(Graff Z, Wachter F, Eapen M, Lehmann L, Cooper T.) Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e438690 PMID: 38862135 06/12/2024
Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial.

(Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, Haight AE, Haines H, Jacobsohn D, Jaroscak J, Kasow KA, Krishnamurti L, Levine JE, Leung K, Margolis D, Yu LC, Horowitz MM, Kamani N, Walters MC, Shenoy S.) Am J Hematol. 2024 Apr;99(4):785-788 PMID: 38343182 PMCID: PMC10947844 SCOPUS ID: 2-s2.0-85185139592 02/12/2024
Corrigendum to Endpoint selection and evaluation in hematology studies [Best Pract Res Clin Haematol 36 (2023) 101479].

(Brazauskas R, Eapen M, Wang T.) Best Pract Res Clin Haematol. 2024 Mar;37(1):101540 PMID: 38490768 SCOPUS ID: 2-s2.0-85185562266 03/16/2024
One's expectations for normality

(Eapen M.) Blood. 3 October 2024;144(14):1469-1470 SCOPUS ID: 2-s2.0-85204711177 10/03/2024
Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study

(Eapen M, Antin JH, Tolar J, Arai S, Horwitz ME, Kou J, Leifer E, McCarty JM, Nakamura R, Pulsipher MA, Rowley SD, Horowitz MM, Deeg HJ.) eClinicalMedicine. October 2024;76 SCOPUS ID: 2-s2.0-85202953543 10/01/2024
Choosing donors in clinical practice

(Eapen M.) Blood. 18 July 2024;144(3):248-249 SCOPUS ID: 2-s2.0-85198150047 07/18/2024
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479] (Best Practice & Research Clinical Haematology (2023) 36(3), (S1521692623000403), (10.1016/j.beha.2023.101479))

(Brazauskas R, Eapen M, Wang T.) Best Practice and Research: Clinical Haematology. March 2024;37(1) SCOPUS ID: 2-s2.0-85185562266 03/01/2024
Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States.

(Lin M, Estrada-Merly N, Eapen M, Zamora AE, Pezzin LE, Winn AN, Philip J, Schinke C, Drobyski WR, Anderson LD Jr, D'Souza A.) Bone Marrow Transplant. 2023 Dec;58(12):1400-1402 PMID: 37673983 SCOPUS ID: 2-s2.0-85170080925 09/07/2023
No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma.

(Knight TE, Ahn KW, Hebert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, Auletta JJ, Kent M, Hashem H, Talano JA, Rotz SJ, Fraint E, Myers KC, Leung W, Sharma A, Bhatt NS, Driscoll TA, Yu LC, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA.) Bone Marrow Transplant. 2023 Dec;58(12):1390-1393 PMID: 37666957 PMCID: PMC11221560 SCOPUS ID: 2-s2.0-85169665242 09/05/2023
Endpoint selection and evaluation in hematology studies

(Brazauskas R, Eapen M, Wang T.) Best Practice and Research: Clinical Haematology. September 2023;36(3) SCOPUS ID: 2-s2.0-85161313534 09/01/2023